- Apixaban, a new oral antithrombotic agent - Review of marketing authorisation studies2012 | Second Faculty of Medicine
- Rivaroxaban - a newly marketed antithrombotic agent2009 | First Faculty of Medicine
- Dabigatran etexilate - a new promising antithrombotic agent2010 | First Faculty of Medicine, Third Faculty of Medicine
- Anticoagulation with new antithrombotic agents - recommendations for daily practice2013 | Publication without faculty affiliation
- Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction2015 | Second Faculty of Medicine
- 2022 Summary of recommendations for long-term secondary prevention after myocardial infarction2022 | First Faculty of Medicine
- Thromboembolism and anticoagulant therapy, insight and perspective2010 | First Faculty of Medicine
- The prevalence of CYP2C9 and VKORC1 polymorphisms in the Czech Republic and reflect on the views of anticoagulation therapy with warfarin2011 | First Faculty of Medicine
- New antithrombotics in the prevention of venous thromboembolia and new anti-platelet drugs2011 | Faculty of Medicine in Hradec Králové
- Drug-Related Hospital Admissions via the Department of Emergency Medicine: A Cross-Sectional Study From the Czech Republic2022 | Faculty of Pharmacy in Hradec Králové
- Should We Replace the Terms Intrinsic and Extrinsic Coagulation Pathways With Tissue Factor Pathway?2017 | Faculty of Medicine in Hradec Králové
- Dabigatran in the prevention of stroke in patients with atrial fibrilation2011 | First Faculty of Medicine, Third Faculty of Medicine
- Thrombosis - the central problem in clinical cardiology2013 | Third Faculty of Medicine
- Benefits and risks of clopidogrel use in patients with coronary artery disease: Evidence from randomized studies and registries2008 | Third Faculty of Medicine, Central Library of Charles University
- Hospital admissions to geriatric ward related to adverse drug events: a cross-sectional study from the Czech Republic2021 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS2004 | Third Faculty of Medicine
- Potentially clinically significant drug-drug interactions in older patients admitted to the hospital: A cross-sectional study2023 | Faculty of Pharmacy in Hradec Králové